| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
|
Still deciding? Get samples of US$ 200/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Mildronate is a structural analog of carnitine that competes in the inhibition of butyrate betaine hydroxylase, thereby inhibiting the biosynthesis of carnitine, which directly inhibits the transport of carnitine-dependent fatty acids in mitochondria. Inhibition of carnitine biosynthesis can reduce the concentration of intracellular free carnitine and prevent isoproterenol-induced acyl carnitine accumulation. Therefore, the drug has a significant protective effect on the myocardium, resulting in this protective effect at the same time on the hemodynamic parameters had no significant effect, cardiac blood supply and cardiac oxygen consumption was no significant change.
| Product Name | Mildronate |
| CAS NO. | 76144-81-5 |
| Purity | 99% |
| Grade Standard | Medical Standard |
| MF | C6H14N2O2 |
| MW | 146.18756 |
| Test Method | HPLC |
| Other Name | Mildronate Powder |
| Appearance | White Powder |
| Brand | MT |
Cardiovascular disease - stable angina, chronic heart failure, cardiomyopathy, functional cardiovascular system failure;
1. Mildronate powder is a novel cardioprotective agent.
2.Mildronate acts on mitochondria at the cellular level to improve myocardial energy metabolism. In view of these drugs and other anti-myocardial ischemia significantly different, also known as cell anti-ischemic drugs.
3. Mildronate is a structural analog of carnitine that competes in the inhibition of butyrate betaine hydroxylase, thereby inhibiting the biosynthesis of carnitine, which directly inhibits the transport of carnitine-dependent fatty acids in mitochondria. Inhibition of carnitine biosynthesis can reduce the concentration of intracellular free carnitine and prevent isoproterenol-induced acyl carnitine accumulation.
){kind=link}